CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show:
* good safety and tolerability
* a high degree of efficacy
* very good persistence
* an acceptable level of exhaustion